{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":6,"sponsored":0,"items":[{"id":"n_cfsg76rdbx6fwxzjkyta","seq":1411947,"kind":"article","title":"Head-To-Head Review: WAVE Life Sciences (NASDAQ:WVE) versus Tonix Pharmaceuticals (NASDAQ:TNXP)","url":"https://www.tickerreport.com/banking-finance/13606701/head-to-head-review-wave-life-sciences-nasdaqwve-versus-tonix-pharmaceuticals-nasdaqtnxp.html","published":"2026-10-02T18:37:17Z","seen":"2026-10-02T18:37:17Z","lang":"en","source":{"id":"tickerreport.com","name":"tickerreport.com","domain":"tickerreport.com"},"via":"gdelt-gkg-english","topics":["economy","crime","health","business"],"authors":["Joseph Griffin"],"entities":[{"id":"Q91396922","name":"Wave Life Sciences","type":"org"},{"id":"Q39052499","name":"Tonix Pharmaceuticals","type":"org"}],"story":"st_cfsg76rdbx6fwxzjkyta","category":"health","category_p":0.36,"category2":"economy-business","sentiment":"neutral","tone":0.09,"political":0.03},{"id":"n_m6ro4mw4gkd3tjuezula","seq":1410878,"kind":"article","title":"Tonix Pharmaceuticals (NASDAQ:TNXP) & WAVE Life Sciences (NASDAQ:WVE) Head to Head Contrast","url":"https://www.dailypolitical.com/2026/10/02/tonix-pharmaceuticals-nasdaqtnxp-wave-life-sciences-nasdaqwve-head-to-head-contrast.html","published":"2026-10-02T18:37:17Z","seen":"2026-10-02T18:37:17Z","lang":"en","source":{"id":"dailypolitical.com","name":"dailypolitical.com","domain":"dailypolitical.com"},"via":"gdelt-gkg-english","topics":["economy","crime","health","science"],"authors":["Trevor Kearing"],"entities":[{"id":"Q39052499","name":"Tonix Pharmaceuticals","type":"org"},{"id":"Q91396922","name":"Wave Life Sciences","type":"org"}],"story":"st_cfsg76rdbx6fwxzjkyta","category":"economy-business","category_p":0.35,"category2":"health","sentiment":"neutral","tone":0.1,"political":0.02},{"id":"n_gyevjnq4wq6ghpkxa3tq","seq":1281436,"kind":"article","title":"WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock Has Consensus Target Price of $22.31 According to Analysts","url":"https://www.dailypolitical.com/2026/10/01/wave-life-sciences-ltd-nasdaqwve-stock-has-consensus-target-price-of-22-31-according-to-analysts.html","published":"2026-10-02T06:40:09Z","seen":"2026-10-02T06:40:09Z","lang":"en","source":{"id":"dailypolitical.com","name":"dailypolitical.com","domain":"dailypolitical.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Latisha Jones"],"entities":[{"id":"Q91396922","name":"Wave Life Sciences","type":"org"}],"story":"st_gyevjnq4wq6ghpkxa3tq","category":"economy-business","category_p":0.54,"sentiment":"neutral","tone":0.28,"political":0.02},{"id":"n_e7g5lj4kdg4cvhs7mevq","seq":1135078,"kind":"article","title":"Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD","url":"https://www.manilatimes.net/2026/10/01/tmt-newswire/globenewswire/wave-life-sciences-announces-fda-feedback-supports-registrational-pathway-for-wve-006-rna-editing-in-aatd/2437002","published":"2026-10-01T11:40:00Z","seen":"2026-10-01T12:23:53Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business","science"],"entities":[{"id":"Q91396922","name":"Wave Life Sciences","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q622437","name":"alpha-1-antitrypsin deficiency","type":"other"}],"story":"st_nh7zjeoy5gh4rbbe6m2a","category":"science-technology","category_p":0.75,"sentiment":"neutral","tone":0.1,"political":0.03},{"id":"n_vh655tugrcdjojn4w47a","seq":890180,"kind":"press_release","title":"Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development","url":"https://www.globenewswire.com/news-release/2026/09/30/3371781/0/en/wave-life-sciences-announces-gsk-s-selection-of-sirna-program-to-transition-to-gsk-for-further-development.html","summary":"Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing","published":"2026-09-30T11:30:00Z","seen":"2026-09-30T11:32:38Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:wve","sg9999014716"],"entities":[{"id":"Q91396922","name":"Wave Life Sciences","type":"org"},{"id":"Q212322","name":"GSK","type":"org"}],"mentions":2,"story":"st_vh655tugrcdjojn4w47a","category":"science-technology","category_p":0.68,"sentiment":"positive","tone":0.57,"political":0.02},{"id":"n_eheymhfh6jwpm5kb6ooq","seq":254597,"kind":"article","title":"Critical Survey: WAVE Life Sciences (NASDAQ:WVE) versus Regeneron Pharmaceuticals (NASDAQ:REGN)","url":"https://www.tickerreport.com/banking-finance/13598446/critical-survey-wave-life-sciences-nasdaqwve-versus-regeneron-pharmaceuticals-nasdaqregn.html","published":"2026-09-27T14:10:37Z","seen":"2026-09-27T14:10:37Z","lang":"en","source":{"id":"tickerreport.com","name":"tickerreport.com","domain":"tickerreport.com"},"via":"gdelt-gkg-english","topics":["economy","health","business","science"],"authors":["Shane Hupp"],"entities":[{"id":"Q91396922","name":"Wave Life Sciences","type":"org"},{"id":"Q7308054","name":"Regeneron Pharmaceuticals","type":"org"}],"story":"st_eheymhfh6jwpm5kb6ooq","category":"health","category_p":0.55,"category2":"economy-business","sentiment":"neutral","tone":0.11,"political":0.03}]}